Bad Blood: Secrets and Lies in a Silicon Valley Startup — Chapter-by-Chapter Outline

Author: John Carreyrou First published: 2018 Edition covered: Current Vintage paperback / reprint edition, ISBN 9780525431992, listed by Penguin Random House and Google Books as 400 pages and carrying a new afterword covering Elizabeth Holmes's trial and sentencing. The numbered narrative spine is the 2018 Alfred A. Knopf first edition: Author's Note, Prologue, 24 numbered chapters, Epilogue, Acknowledgments, Notes, and Index. Library and Google Books records confirm the ordered 24-chapter structure; the later Vintage material adds afterword coverage rather than changing the numbered chapters.

Central thesis

Bad Blood argues that Theranos became a major corporate fraud because a medical device company was allowed to behave like an opaque software startup while claiming to handle real patients' blood tests. Elizabeth Holmes's charisma, secrecy, board access, legal aggression, and Silicon Valley "visionary founder" mythology repeatedly substituted for evidence that the technology worked.

The book's organizing claim is not that ambition itself caused the fraud. The failure came from the interaction of ambition with weak verification: investors accepted stories, partners feared missing the next large platform, board members deferred to prestige, employees were isolated from one another, and dissenters were punished. In health care, that combination created direct patient risk.

Carreyrou also makes investigative reporting part of the structure. The early chapters show fraud being built inside the company; the later chapters show how employees, doctors, regulators, and reporters slowly assemble enough external evidence to break through Theranos's secrecy.

How did a company with broken blood-testing technology persuade investors, partners, board members, and the public that it was revolutionizing medicine?

Author's Note

Central question

How should readers understand the evidentiary basis for a book built from private conversations, legal records, and confidential sources?

Main argument

Reporting as foundation. Carreyrou states that the account rests on interviews with more than 150 people, including many former Theranos employees, plus emails, documents, depositions, and other records. The note matters because the book often reconstructs closed-door scenes that Theranos worked hard to keep hidden.

Limits and refusals. Holmes did not cooperate with the book, and some sources are anonymized. The note frames the narrative as a reported reconstruction, not omniscient biography.

Key ideas

• The book's authority depends on source triangulation rather than access to Holmes.
• Confidentiality is part of the story because Theranos used secrecy and legal threats to control information.
• The note prepares readers to treat quoted scenes as grounded in documents or witness recollection.

Key takeaway

The book begins by making its method visible: the Theranos story has to be reconstructed from the evidence the company tried to suppress.

Prologue

Central question

What first reveals the gap between Theranos's public demonstrations and its actual technology?

Main argument

A staged success. In 2006, after a Novartis demonstration in Europe, Theranos founder Elizabeth Holmes celebrates a supposed breakthrough. CFO Henry Mosley learns that the demo depended on a device working only intermittently and that employees had used misleading presentation tactics.

A pattern established. Mosley confronts Holmes about fooling investors. Instead of treating the warning as a governance problem, Holmes fires him. The prologue condenses the book's larger pattern: bad technical news is reframed as disloyalty, and the person who raises it is removed.

Key ideas

• The fraud begins before Theranos is famous; deception is already present in early demos.
• Finance, science, and governance are separated from one another inside the company.
• Holmes's response to truth-telling is exclusion, not correction.

Key takeaway

The prologue shows Theranos choosing narrative control over technical reality at an early moment when correction was still possible.

Chapter 1 — A Purposeful Life

Central question

Where do Holmes's ambition, self-conception, and first company idea come from?

Main argument

Ambition before product. Holmes is presented as intensely competitive from childhood, raised in a family that prizes distinction and public purpose. Her desire to become wealthy and consequential precedes any particular medical invention.

The Stanford origin story. At Stanford, she studies chemical engineering, works with Channing Robertson, and develops an idea for a diagnostic and drug-delivery patch after exposure to SARS-related work in Asia. She drops out to build the company, first called Real-Time Cures and then Theranos, a blend of therapy and diagnosis.

Key ideas

• The chapter frames Holmes's ambition as both genuine and dangerous when separated from expertise.
• Stanford credibility and Robertson's support help convert a student idea into a fundable startup.
• The original patch idea gives way to a cartridge-and-reader blood-testing concept.
• Early investors are buying founder promise as much as demonstrated technology.

Key takeaway

Theranos begins with a compelling mission and unusually strong founder confidence, but the company forms before the technology is proven.

Chapter 2 — The Gluebot

Central question

Why does the first Theranos device become technically unstable almost immediately?

Main argument

The engineering constraint. Edmond Ku is hired to turn the early reader into a usable product, but Holmes insists on extremely small blood samples and small cartridges. That forces dilution, fluid handling, valves, reagents, and contamination problems into a device that must work like a laboratory.

Secrecy blocks problem-solving. Holmes restricts communication between engineering and chemistry, then creates a rival team under Tony Nugent. Nugent's team uses a glue-dispensing robot to automate lab steps; the resulting prototype is called Edison, though employees call it the gluebot. The device is taken to demos before it is truly validated.

Key ideas

• Miniaturizing laboratory chemistry creates hard physical constraints, not merely design challenges.
• Departmental isolation prevents engineers and scientists from resolving shared problems.
• Holmes treats technical delay as resistance rather than information.
• The Edison emerges as a workaround, not as a mature medical device.

Key takeaway

The first device is built through pressure and improvisation, and the company begins selling confidence before it has reliability.

Chapter 3 — Apple Envy

Central question

How does Holmes's imitation of Apple shape Theranos's product and culture?

Main argument

Borrowing the aesthetic. Holmes hires Apple designers, adopts black turtlenecks, and imagines the Edison as the "iPod of health care." She wants medical testing to feel as sleek and closed as consumer electronics.

Borrowing the secrecy without the discipline. Apple-like secrecy becomes an excuse for surveillance, controlled communication, and withholding product facts from board members. Avie Tevanian, a former Apple executive on the board, notices gaps between claims and sales reality; when he presses, he is pushed out. Ana Arriola also leaves after raising product concerns.

Key ideas

• Apple becomes a model for branding, secrecy, and founder mythology.
• Medical devices cannot be validated by industrial design or launch theater.
• Experienced insiders see inconsistencies that the board chooses not to confront.
• Product concern is again treated as disloyalty.

Key takeaway

Holmes imports the symbols of Apple without the working product discipline that made Apple's secrecy defensible.

Chapter 4 — Goodbye East Paly

Central question

What happens when Theranos tries to look like a mature company before it has become one?

Main argument

A move for legitimacy. Theranos leaves East Palo Alto for a more impressive Palo Alto address. The move signals progress to investors and partners, but it also raises costs and deepens the company's need to maintain appearances.

Governance almost intervenes. Internal executives question revenue projections and pharmaceutical relationships. The board briefly moves toward removing Holmes as CEO, but she wins them back through contrition and persuasion, then fires the executives who surfaced the problem.

Key ideas

• Physical polish becomes a substitute for operational maturity.
• Board oversight fails at the point where it might have changed the company's path.
• Employees learn that escalating concerns can end their careers.
• Theranos's outward legitimacy depends on suppressing inconvenient internal information.

Key takeaway

The board nearly corrects the company's direction but ultimately reinforces Holmes's control.

Chapter 5 — The Childhood Neighbor

Central question

How does Richard Fuisz become an external antagonist in the Theranos story?

Main argument

A personal grievance becomes a patent fight. Richard Fuisz, a medical inventor and family acquaintance, feels slighted that Holmes did not consult him. He studies Theranos's concept and files a patent aimed at a comparison-chip idea he thinks the device would need.

Early signs of the legal battlefield. The dispute begins as family resentment, but it foreshadows the legal war Theranos will use against critics. Fuisz is not portrayed as a whistleblower at this stage; he is a combative operator pursuing leverage.

Key ideas

• The chapter broadens the story beyond Theranos's walls.
• Intellectual property becomes a weapon before the technology is settled.
• Personal pride and business strategy are difficult to separate.
• Theranos's later legal aggression has an early counterpart in this conflict.

Key takeaway

The Fuisz conflict introduces the legal and personal vendettas that will later surround Theranos.

Chapter 6 — Sunny

Central question

What does Sunny Balwani add to Holmes's leadership system?

Main argument

Power without transparency. Sunny Balwani, Holmes's much older romantic partner, enters Theranos as a powerful executive while the relationship is hidden from many stakeholders. He becomes operational enforcer, feared for blunt orders, firings, and intimidation.

International demos under strain. Theranos pursues demonstrations in Belgium, Mexico, and Thailand even as the Edison remains unreliable. Balwani reinforces the company's tendency to push ahead despite technical failure, converting urgency into coercion.

Key ideas

• Balwani amplifies secrecy, fear, and top-down control.
• The hidden relationship creates a governance problem inside the executive team.
• Demonstrations continue despite device failures and sample-handling problems.
• Departures are managed to control the story employees hear.

Key takeaway

Balwani makes the company more forceful but less capable of admitting technical reality.

Chapter 7 — Dr. J

Central question

Why does Walgreens move toward Theranos despite warning signs?

Main argument

Fear of missing the future. Walgreens executive Jay Rosan, known as Dr. J, becomes excited by the chance to turn drugstores into health destinations. Walgreens sees Theranos as a platform that could keep it ahead of CVS and other rivals.

Due diligence is blocked. Consultant Kevin Hunter notices that Theranos refuses lab access, avoids direct demonstrations, and cannot clearly explain test capabilities. His concerns lose to strategic fear: if Theranos is real, Walgreens does not want a competitor to get it first.

Key ideas

• Competitive pressure makes weak evidence feel acceptable.
• Theranos uses secrecy to prevent normal partner diligence.
• The promise of many tests from tiny samples exceeds what the Edison can do.
• Walgreens's internal skeptics lack enough authority to stop the deal.

Key takeaway

Walgreens illustrates how a large partner can rationalize risk when the imagined upside is strategically frightening.

Chapter 8 — The miniLab

Central question

Can Theranos solve the Edison problem by building a more advanced machine?

Main argument

More functions, more complexity. The miniLab is meant to combine multiple testing technologies into a desktop device: chemistry, immunoassay, hematology, and other functions in one box. Holmes insists on miniaturization before the system is proven at normal scale.

Culture undermines engineering. Engineers see nepotism, secrecy, and unrealistic demands. Holmes's reaction to Kent Frankovich's bicycle light project shows how total commitment to Theranos becomes a loyalty test. Technical challenge is compounded by founder control.

Key ideas

• The miniLab raises the scientific difficulty rather than resolving the Edison flaws.
• Holmes prioritizes small form factor over staged validation.
• Employees are expected to subordinate outside intellectual life to Theranos.
• The company mistakes intensity for engineering progress.

Key takeaway

The miniLab is presented as the next breakthrough, but it inherits the same mismatch between ambition and validation.

Chapter 9 — The Wellness Play

Central question

How does Safeway become trapped in Theranos's promise?

Main argument

Retail transformation. Safeway CEO Steve Burd wants health clinics to revive the grocery chain and spends heavily remodeling stores. Theranos is supposed to supply the diagnostic engine for this wellness strategy.

Evidence ignored inside the partner. Safeway physician Kent Bradley sees long delays, venous draws, outsourced tests, inconsistent results, and idle clinics. Burd discounts those warnings because the strategic commitment is already large.

Key ideas

• Safeway invests hundreds of millions in clinics before Theranos proves readiness.
• The Theranos service does not match the finger-stick story promised to partners.
• Abnormal or inconsistent results appear in internal testing.
• Sunk costs make Safeway more willing to wait.

Key takeaway

Safeway shows how a partner can become committed to Theranos's story before the underlying service exists.

Chapter 10 — "Who Is LTC Shoemaker?"

Central question

What happens when military and regulatory scrutiny enters the Theranos narrative?

Main argument

The military channel. Holmes pitches General James Mattis on battlefield blood testing. Lieutenant Colonel David Shoemaker, responsible for medical-device review, asks for proper FDA and military compliance.

Regulation as obstacle. Holmes resents Shoemaker's insistence on process. CMS inspector Gary Yamamoto later sees a conventional lab rather than the promised technology. The chapter shows that knowledgeable review can puncture Theranos's mystique, but only if institutions insist on standards.

Key ideas

• Military prestige gives Theranos another validation story.
• Shoemaker represents domain-specific scrutiny that Holmes cannot charm away.
• Theranos's actual lab setup diverges from its device narrative.
• Regulatory boundaries slow the company but do not yet stop it.

Key takeaway

The chapter contrasts prestige-based persuasion with the ordinary compliance rules medical technology must satisfy.

Chapter 11 — Lighting a Fuisz

Central question

How does Theranos use litigation to intimidate and exhaust an opponent?

Main argument

The patent fight escalates. Theranos sues Richard Fuisz and his sons, alleging theft of patent information. David Boies and Boies Schiller bring high-cost legal pressure that Fuisz struggles to match.

Litigation as strategy. The suit is not just about one patent. It shows Theranos's willingness to use aggressive legal tactics, surveillance, and financial pressure to control threats. Boies also becomes closer to the company through board involvement and stock compensation.

Key ideas

• The Fuisz case previews later attacks on employees, sources, and reporters.
• Legal intimidation substitutes for transparent technical proof.
• Boies's role blurs outside counsel, investor, and board participant.
• Theranos can turn wealth and prestige into pressure on critics.

Key takeaway

Theranos learns that expensive legal force can silence or exhaust opponents, at least temporarily.

Chapter 12 — Ian Gibbons

Central question

What does Ian Gibbons's experience reveal about the human cost of Theranos's secrecy?

Main argument

A scientist trapped inside the fraud. Ian Gibbons, Theranos's first major scientific hire, knows the assays and devices are not performing as claimed. He is marginalized after raising concerns, then rehired with reduced authority.

Pressure from the patent case. Gibbons faces a deposition that could expose problems with Theranos's patents and Holmes's claimed inventorship. Under severe stress, he attempts suicide and later dies. The company's muted response signals how little room remains for ordinary human obligation.

Key ideas

• Gibbons embodies real scientific expertise inside a company led by marketing claims.
• Secrecy prevents the collaboration needed to fix assay problems.
• Legal exposure and technical truth become psychologically unbearable.
• Theranos treats a death as reputational risk rather than institutional failure.

Key takeaway

Gibbons's death marks the point where Theranos's culture of concealment becomes visibly destructive to the people inside it.

Chapter 13 — Chiat\Day

Central question

How does Theranos prepare a public identity stronger than its product?

Main argument

Advertising before proof. Theranos hires TBWA\Chiat\Day, Apple's advertising agency, to build an elegant public brand. Slogans, the Flower of Life logo, nanotainer imagery, and app concepts present testing as simple, humane, and modern.

Claims are softened but not fixed. Agency staff become uneasy with assertions about hundreds of tests, accuracy, and FDA approval. Some language is moderated, but the core message still implies a finished revolution that the lab cannot deliver.

Key ideas

• Branding gives Theranos a consumer-health aura before medical validation.
• The nanotainer becomes a powerful symbol of the finger-stick promise.
• Outside creatives notice claims that seem too strong.
• Public launch pressure grows while technical readiness lags.

Key takeaway

Theranos builds a polished public story that makes later technical doubts harder for outsiders to see.

Chapter 14 — Going Live

Central question

What does it take for Theranos to launch in Walgreens stores despite unresolved device failures?

Main argument

Launch pressure wins. After repeated delays, Holmes commits to going live in Walgreens. Inside the company, engineers and scientists know the devices are not ready and scramble to adapt conventional equipment and procedures.

Dissent becomes heresy. Employees who object on ethical or scientific grounds leave or are pushed out. Holmes frames the company's work as a calling, making skepticism appear morally suspect rather than professionally necessary.

Key ideas

• Retail launch converts internal device problems into patient-facing risk.
• Conventional machines and workarounds fill the gap left by Theranos technology.
• H-1B and junior employees are especially vulnerable to pressure.
• The company treats readiness as a public deadline, not a scientific threshold.

Key takeaway

Theranos goes live by forcing reality to fit a launch date rather than delaying until the service is safe and honest.

Chapter 15 — Unicorn

Central question

How does Theranos convert media attention into a multibillion-dollar valuation?

Main argument

Prestige compounds. A favorable Wall Street Journal profile, endorsements from George Shultz and other board figures, and Silicon Valley's unicorn boom make Theranos look like the next major platform company.

Investor theater. Visitors see security, charts, and selective demonstrations, but not the full truth about conventional machines, cherry-picked data, or fabricated projections. The company's value reaches $9 billion, and Holmes's paper wealth rises with it.

Key ideas

• Media credibility makes later fundraising easier.
• Board prestige acts as a substitute for technical diligence.
• Financial projections are detached from operational reality.
• The unicorn label makes skepticism feel like missing a historic company.

Key takeaway

Theranos becomes most valuable when the distance between its story and its technology is widest.

Chapter 16 — The Grandson

Central question

How does Tyler Shultz move from believer to whistleblower?

Main argument

Inside the lab. Tyler Shultz, George Shultz's grandson, joins Theranos because he believes in the mission. He sees data cherry-picking, repeated testing to average bad results, and proficiency testing practices that appear improper.

Family loyalty versus evidence. Tyler raises concerns with Holmes and Balwani, then with his grandfather. George Shultz trusts Holmes more than Tyler's documentation. Erika Cheung, another lab employee, shares Tyler's concerns and also leaves.

Key ideas

• Tyler's disillusionment matters because he enters as a true believer.
• Lab quality problems are not abstract; they affect reportable patient results.
• Prestigious board loyalty can override family evidence.
• Whistleblowing begins before journalism enters the story.

Key takeaway

Tyler Shultz shows how direct evidence can still fail when authority figures are emotionally invested in the fraud.

Chapter 17 — Fame

Central question

How does Holmes become a public icon while the company's problems continue?

Main argument

The media story hardens. Roger Parloff's Fortune cover story and other appearances turn Holmes into a symbol of female entrepreneurship and medical disruption. TEDMED, celebrity treatment, and elite events strengthen the aura.

Marketing absorbs the company. Patrick O'Neill and others build offices, videos, and campaigns around Holmes's image. Errol Morris ads for Walgreens are pulled when the finger-stick story conflicts with actual venous draws, but the public myth remains powerful.

Key ideas

• Fame makes Theranos harder to question because many institutions have endorsed it.
• Holmes becomes the company's main product in public.
• The Fuisz patent case ends, removing one nuisance but not the underlying truth.
• Patient-facing reality continues to diverge from advertising.

Key takeaway

Holmes's fame gives Theranos more protection precisely when it needs more scrutiny.

Chapter 18 — The Hippocratic Oath

Central question

What pushes medical insiders to expose the patient-risk side of Theranos?

Main argument

A laboratory conscience. Lab director Alan Beam sees proficiency-testing cheating, hidden quality-control data, and inaccurate results. He resigns after concluding that the company's conduct violates medical obligations.

The information chain begins. Beam speaks with Richard Fuisz, who points the story toward medical blogger Adam Clapper. Clapper, skeptical of Theranos's claims, eventually connects the concerns to Carreyrou.

Key ideas

• The chapter foregrounds patient safety, not just investor deception.
• Beam's resignation shows the conflict between professional ethics and corporate pressure.
• Theranos uses legal threats to force former insiders to delete or hide evidence.
• The first route to the press is indirect and fragile.

Key takeaway

The story becomes urgent when insiders frame Theranos not as startup exaggeration but as a medical risk.

Chapter 19 — The Tip

Central question

How does Carreyrou begin turning rumors into a reportable investigation?

Main argument

Building corroboration. Carreyrou hears from Clapper, contacts the Fuiszes, Rochelle Gibbons, Alan Beam, Tyler Shultz, Erika Cheung, physicians, patients, and lab experts. Each source supplies a different piece: technology failure, bad test results, hidden conventional machines, and internal fear.

Testing the test. In Arizona, Carreyrou and Dr. Nicole Sundene compare Theranos and LabCorp results. The discrepancies give the investigation patient-level evidence to accompany insider testimony.

Key ideas

• The investigation works by assembling independent confirmations.
• Emails and documents matter because Theranos disputes personal recollections.
• Patient stories show concrete harm from inaccurate results.
• Tyler and Erika become central because they saw the lab practices directly.

Key takeaway

Carreyrou's investigation gains force by connecting insider knowledge to patient evidence and documents.

Chapter 20 — The Ambush

Central question

How does Theranos respond when it suspects employees are speaking to the press?

Main argument

Pressure on Tyler. Boies Schiller lawyers confront Tyler Shultz at George Shultz's house, pushing him to sign statements and reveal sources. Tyler refuses, but the encounter puts his family under severe stress and financial strain.

Pressure on the reporter. Theranos tries to identify sources and intimidate the Journal investigation. The chapter shows the company's old pattern applied externally: isolate, threaten, and force silence before facts can circulate.

Key ideas

• Legal intimidation shifts from competitors to whistleblowers.
• Family relationships become tools in the pressure campaign.
• Tyler's refusal preserves a crucial source channel.
• The company's behavior confirms the importance of the information it is trying to suppress.

Key takeaway

Theranos's response to scrutiny is not transparency but coercion aimed at the people who can verify the truth.

Chapter 21 — Trade Secrets

Central question

How does Theranos use trade-secret claims to fight publication?

Main argument

The secrecy defense. Theranos argues that questions about its technology and lab processes threaten confidential information. Boies's team pushes the Journal to abandon or narrow the story.

Journalistic standards. Carreyrou and his editors keep checking facts, seeking company comment, and protecting sources. The chapter contrasts trade-secret rhetoric with the public interest in accurate medical testing.

Key ideas

• Trade secrets can be legitimate, but Theranos uses the concept to block accountability.
• Publication requires stronger verification because the legal threat is serious.
• The Journal's institutional backing matters; an isolated blogger or employee could be overwhelmed.
• The central issue is not proprietary detail but whether public claims are true.

Key takeaway

The chapter makes secrecy itself the contested issue: protection of innovation cannot justify misleading patients and partners.

Chapter 22 — La Mattanza

Central question

What final pressure campaign precedes the Journal's first major story?

Main argument

The tuna slaughter metaphor. The title refers to a staged trap, and the chapter depicts Theranos trying to corner sources and the Journal before publication. Lawyers, private investigators, and executives move to discredit or frighten people around the story.

The story holds. Despite threats, the investigation has enough independent sourcing to proceed. Theranos's tactics reveal desperation and confirm the stakes of external scrutiny.

Key ideas

• Theranos tries to make source cooperation feel personally ruinous.
• Legal spectacle is used to create doubt before facts are public.
• Carreyrou's source network survives because multiple people independently confirm the same pattern.
• The company's defensive behavior becomes part of the story.

Key takeaway

Theranos attempts to trap its critics, but the evidence base is now too broad to contain.

Chapter 23 — Damage Control

Central question

How does Theranos react after the Journal exposes the technology problems?

Main argument

Public denial. After the first article, Holmes attacks the reporting and presents the story as an attack on innovation. Theranos insists it is being misunderstood while still failing to provide the transparent validation the criticism demands.

Regulatory consequences. FDA and CMS scrutiny intensifies. The nanotainer and testing practices come under pressure, partners and observers reassess the company, and the old aura begins to weaken.

Key ideas

• Theranos uses the language of innovation to avoid answering factual claims.
• The Journal story changes incentives for regulators and partners.
• Damage control cannot solve the underlying lab deficiencies.
• The company loses the ability to manage information quietly.

Key takeaway

Once the story is public, Theranos can still deny, but it can no longer fully control who investigates.

Chapter 24 — The Empress Has No Clothes

Central question

How does the Theranos illusion finally collapse?

Main argument

Official findings replace private suspicion. Regulators document serious lab deficiencies, Walgreens and other partners withdraw, and Theranos voids or corrects large volumes of test results. The claims that once attracted investors now become evidence of deception.

Scapegoating and survival attempts. Holmes separates from Balwani and tries to blame him, but the company has lost credibility. Lawsuits, enforcement actions, and partner exits leave little of the original enterprise.

Key ideas

• Regulatory inspection turns whistleblower allegations into official findings.
• Business partners retreat once reputational and legal risks exceed upside.
• Patient test invalidations show the human stakes of the fraud.
• The title captures the collapse of a shared illusion sustained by prestige.

Key takeaway

Theranos falls when outside institutions finally verify what insiders had long known: the technology did not match the claims.

Epilogue

Central question

What remains of Theranos after the public collapse?

Main argument

The final technical admission. Theranos later publishes material about the miniLab, but the disclosed system does not support the grand promise of many accurate tests from a tiny finger-stick sample. The company cannot retroactively make the original claims true.

Accountability begins. Civil and criminal proceedings follow, and the company's valuation effectively disappears. The epilogue closes the 2018 narrative by showing that belated disclosure is not vindication.

Key ideas

• Theranos's late technical description is narrower than its public claims.
• The company loses market, partner, and investor confidence.
• Legal consequences begin after the reporting and regulatory process.
• The epilogue returns to data: evidence eventually outlasts narrative.

Key takeaway

The epilogue shows that Theranos's end is not a failed launch but the exposure of years of unsupported claims.

Afterword — Vintage Books / Post-Sentencing Material

Edition note

The Vintage paperback / reprint edition adds afterword material to the first-edition structure. Current publisher and Google Books listings describe this material as covering Holmes's trial and sentencing.

Central question

How did the post-publication legal process close the gap between reported fraud and formal accountability?

Main argument

From exposure to verdict. The later material brings the story beyond Theranos's collapse into the criminal trials of Holmes and Balwani. Holmes is convicted on investor-fraud counts, and Balwani is convicted separately.

Sentencing as narrative closure, not full repair. Holmes receives a prison sentence of 135 months, and Balwani receives 155 months. Restitution and punishment do not undo patient anxiety, employee trauma, investor losses, or the damage to trust in medical innovation, but they provide the legal endpoint missing from the original 2018 edition.

Key ideas

• The afterword changes the edition's endpoint from collapse to criminal accountability.
• The trials distinguish legal proof from journalistic exposure.
• Sentencing confirms that the fraud was not merely startup optimism gone wrong.
• The consequences reach investors, patients, employees, and public trust.

Key takeaway

The added afterword completes the arc from private deception to public exposure to criminal punishment.

The book's overall argument

1. Author's Note (Sourcing the account) — The story must be read as a documented reconstruction of a secretive company.
2. Prologue (The first false demo) — Theranos's pattern begins with misleading demonstrations and punishment of internal truth-telling.
3. Chapter 1 (A Purposeful Life) — Holmes's ambition and Stanford credibility create the founder myth before the product works.
4. Chapter 2 (The Gluebot) — The first device exposes the gap between medical complexity and startup improvisation.
5. Chapter 3 (Apple Envy) — Holmes borrows Apple's symbols while using secrecy to hide technical weakness.
6. Chapter 4 (Goodbye East Paly) — The board nearly intervenes but ultimately strengthens Holmes's control.
7. Chapter 5 (The Childhood Neighbor) — The Fuisz dispute introduces intellectual-property conflict and personal vendetta.
8. Chapter 6 (Sunny) — Balwani adds operational intimidation and deepens the culture of fear.
9. Chapter 7 (Dr. J) — Walgreens shows how strategic FOMO can defeat due diligence.
10. Chapter 8 (The miniLab) — The company doubles down on a more complex device instead of validating simpler claims.
11. Chapter 9 (The Wellness Play) — Safeway demonstrates the danger of partner lock-in before proof.
12. Chapter 10 ("Who Is LTC Shoemaker?") — Military and regulatory scrutiny reveal that prestige cannot replace compliance.
13. Chapter 11 (Lighting a Fuisz) — Theranos learns to use legal pressure as a business weapon.
14. Chapter 12 (Ian Gibbons) — The human cost of secrecy becomes visible inside the scientific staff.
15. Chapter 13 (Chiat\Day) — Branding prepares the public story before the technology is ready.
16. Chapter 14 (Going Live) — Retail launch turns internal deception into patient-facing risk.
17. Chapter 15 (Unicorn) — Media, board prestige, and private capital inflate the company at the moment of greatest factual weakness.
18. Chapter 16 (The Grandson) — Tyler Shultz and Erika Cheung show that insiders can see the truth but still be disbelieved.
19. Chapter 17 (Fame) — Holmes's celebrity makes the fraud more socially protected.
20. Chapter 18 (The Hippocratic Oath) — Medical ethics pushes insiders toward external disclosure.
21. Chapter 19 (The Tip) — Carreyrou assembles independent sources, documents, doctors, and patient evidence.
22. Chapter 20 (The Ambush) — Theranos attacks sources rather than answering the substance.
23. Chapter 21 (Trade Secrets) — The company tries to convert secrecy into immunity from reporting.
24. Chapter 22 (La Mattanza) — The last intimidation campaign fails because the evidence has become too distributed.
25. Chapter 23 (Damage Control) — Public exposure shifts power to regulators, partners, and outside scrutiny.
26. Chapter 24 (The Empress Has No Clothes) — Official findings and partner exits collapse the illusion.
27. Epilogue (After collapse) — Late technical disclosures cannot rescue years of false claims.
28. Afterword (Vintage / post-sentencing material) — Criminal verdicts and sentences supply legal closure to the reported story.

Common misunderstandings

Misunderstanding: Theranos was just a normal startup that failed technically.

The book distinguishes failure from deception. Theranos did not merely miss engineering milestones; it kept selling, raising money, and testing patients while hiding that its devices could not perform as claimed.

Misunderstanding: The problem was secrecy by itself.

Secrecy is not inherently fraudulent. The issue is that Theranos used secrecy to prevent validation, silence employees, mislead partners, and avoid the scientific transparency required in medical testing.

Misunderstanding: The board should have caught everything because it was famous.

The board's prestige is part of the problem. Many members had political, military, or diplomatic stature but lacked diagnostic-lab and medical-device expertise, and they deferred to Holmes instead of forcing technical proof.

Misunderstanding: Holmes was simply manipulated by Balwani.

Balwani intensifies the culture of fear, but the book repeatedly shows Holmes originating claims, controlling information, misleading partners, and retaliating against dissent before and alongside him.

Misunderstanding: The fraud harmed only wealthy investors.

Investor losses are important, but the book's sharper ethical issue is patient risk: inaccurate or unreliable tests can lead to fear, follow-up procedures, missed diagnoses, or unnecessary treatment.

Misunderstanding: Carreyrou's reporting caused Theranos to fail.

The reporting exposed failure that already existed. Regulators, patient complaints, lab insiders, and partner experiences all point to underlying technical and operational breakdowns.

Central paradox / key insight

The central paradox of Bad Blood is that Theranos's most valuable asset was not its technology but the belief that its technology must exist because so many prestigious people had endorsed it. Each new endorsement made verification feel less necessary, while each blocked verification made endorsement more important.

The book's key insight is that in regulated, patient-facing science, "fake it until you make it" can become a mechanism for harm. A software demo can be patched later; a clinical test result enters medical decisions immediately. Theranos treated credibility as if it could create technical truth, but medical truth had to be measured, validated, documented, and regulated.

Theranos collapsed because the story scaled faster than the science.

Important concepts

Theranos

The company founded by Elizabeth Holmes to commercialize small-sample blood testing. Its name combines therapy and diagnosis, which captures the broad medical promise it sold.

Edison

The early Theranos blood-testing device, built around automation of lab steps inside a small reader. In practice, it could not perform the broad menu of accurate tests the company suggested.

Gluebot

Employees' nickname for an Edison prototype that used a glue-dispensing robot to move fluids. The nickname undercuts the polished public image by pointing to the improvised engineering underneath.

miniLab

The later device meant to combine multiple laboratory technologies in one desktop machine. It represented Theranos's attempt to solve earlier limitations but increased complexity and remained unready for the claims made about it.

Nanotainer

Theranos's small blood-collection container for finger-stick samples. It became a symbol of the company's promise that tiny samples could replace conventional venous blood draws.

Finger-stick testing

The method of collecting blood from a fingertip rather than from a vein. Theranos's public appeal depended on the claim that this simpler collection method could support a wide range of accurate tests.

Proficiency testing

External quality checks used to validate laboratory accuracy. Theranos's handling of proficiency testing becomes a central sign that the company was concealing device performance rather than measuring it honestly.

Trade secrets

Legitimate confidential business information. Theranos invokes trade secrecy to block scrutiny, but the book argues that secrecy cannot excuse false medical and investor claims.

Unicorn

A private startup valued at more than $1 billion. Theranos's unicorn status increases its prestige and makes investors and partners more afraid of missing out.

Reality distortion field

A phrase associated with Steve Jobs and applied to Holmes's ability to persuade people that difficult or impossible things were true. Carreyrou's account treats the effect as dangerous when not anchored by working technology.

FOMO

Fear of missing out. Walgreens, Safeway, investors, and media figures repeatedly act as if the cost of missing Theranos might be greater than the cost of insufficient verification.

Whistleblower

An insider who discloses wrongdoing. Tyler Shultz, Erika Cheung, Alan Beam, and others become crucial because they connect internal lab practices to external accountability.

CMS and FDA

Federal regulators relevant to laboratory and medical-device oversight. Their inspections and actions help turn reported concerns into official findings.

Boies Schiller

The law firm led by David Boies that represents Theranos. In the book, it exemplifies how legal prestige and pressure are used to intimidate critics and sources.

References and Web Links

Primary book and edition information

• John Carreyrou. Bad Blood: Secrets and Lies in a Silicon Valley Startup. Alfred A. Knopf, first edition, 2018; Vintage paperback / reprint edition, 2020 and later publisher-listed reprints.
  • Penguin Random House publisher page for the Vintage paperback, ISBN 9780525431992
  • Google Books record for the 2020 Knopf Doubleday / Vintage edition, including contents and bibliographic data
  • Google Books record for the 2018 Knopf Doubleday edition
  • Camden County Library catalog record with first-edition details and Syndetics table of contents
  • Galveston College Library ISBD record with first-edition details and ordered contents

Background and overview

• Book and author context.
  • Wikipedia overview of Bad Blood: Secrets and Lies in a Silicon Valley Startup
  • Publishers Weekly review and bibliographic entry
  • SuperSummary overview noting the Vintage Books Edition as the basis for its guide

Theranos reporting, enforcement, and legal aftermath

• Primary and official sources on the investigation and legal consequences.
  • John Carreyrou, "Hot Startup Theranos Has Struggled With Its Blood-Test Technology," The Wall Street Journal, October 2015
  • SEC press release: "Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud," March 14, 2018
  • Department of Justice case page: U.S. v. Elizabeth Holmes, et al.
  • DOJ press release on Elizabeth Holmes's 135-month sentence, November 18, 2022
  • DOJ press release on Ramesh "Sunny" Balwani's 155-month sentence, December 7, 2022

Additional chapter summaries and study resources

These are secondary summaries and should be used alongside, rather than instead of, the original book.

• SuperSummary chapter summaries: Author's Note through Chapter 6
• SuperSummary chapter summaries: Chapters 7-10
• SuperSummary chapter summaries: Chapters 11-16
• SuperSummary chapter summaries: Chapter 17 through afterword
• Bookey chapter-summary page for Bad Blood
• The Bibliofile summary and detailed chapter-summary page